CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 103 enrolled
Drug / intervention
ELND005 (scyllo-inositol)drug
Likely dose
ELND005 (scyllo-inositol) 2000 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00934050
NCT00934050Phase 2Completed
CompareCT.gov

A Long-Term Follow-Up Study of Oral ELND005 (AZD-103) in Subjects With Alzheimer's Disease

OPKO Health, Inc.·interventional·Posted Jul 8, 2009·Updated Oct 21, 2019

In Brief

A Phase 2 clinical trial evaluating ELND005 (scyllo-inositol) for Alzheimer's Disease. Completed, enrolled 103 participants across 38 sites in 2 countries.

Detailed Summary

The purpose of this study is to evaluate the long-term safety and tolerability of ELND005 beyond the 18 months of treatment in original randomized and blinded clinical trail ELND005-AD201.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer's Disease
CountriesCanada, United States
Collaborators--

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedJul 8, 2009
Enrollment StartJun 1, 2009
Primary CompletionJun 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 17.0 years ago

Interventions

ELND005 (scyllo-inositol)drug

Prior to 15Dec2009: ELND005 2000 mg PO BID for 48 weeks After 15Dec2009: ELND005 250 mg PO BID for 48 weeks